Placebo News and Research

RSS

Allergan receives FDA approval for Botox to treat overactive bladder

The U.S. Food and Drug Administration today expanded the approved use of Botox (onabotulinumtoxinA) to treat adults with overactive bladder who cannot use or do not adequately respond to a class of medications known as anticholinergics.

18 Jan 2013

Macular pigment screening: an interview with Jaquie Finn, Product Line Manager at Elektron Technology

AMD is the leading cause of vision loss in anyone over 50 and globally in 2010 it was estimated to cost $340 billion to treat AMD. The costs are set to spiral over the next 20 years and really over burden the healthcare system unless people start to take preventative action.

18 Jan 2013

Boehringer Ingelheim initiates enrollment in Phase III IFN-free HCV trial

Today, Boehringer Ingelheim announced that the first patients have been enrolled in the company's pivotal Phase III interferon (IFN)-free hepatitis C (HCV) clinical trial programme, HCVerso.

18 Jan 2013

Children's Oakland recruits patients for deferiprone clinical trial to treat PKAN

A groundbreaking, international clinical trial of an iron chelation drug, deferiprone, to treat the rare and devastating neurodegenerative disease, pantothenate kinase-associated neurodegeneration (PKAN), began last month at the trial's only North American site, Children's Hospital & Research Center Oakland.

17 Jan 2013

Underestimating cough duration may skew antibiotic perceptions

US researchers suggest that one reason patients request antibiotics for respiratory infections is that they greatly underestimate how long it usually takes for acute cough illness to resolve.

17 Jan 2013

Top-line results from Amgen’s Aranesp Phase 3 trial on heart failure and anemia

Amgen today announced top-line results of the Phase 3 Aranesp (darbepoetin alfa) RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.

17 Jan 2013

Protein Sciences receives FDA approval for Flublok vaccine

The U.S. Food and Drug Administration today announced that it has approved Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology. Flublok is approved for the prevention of seasonal influenza in people 18 through 49 years of age.

16 Jan 2013

Coenzyme Q10 supplement may boost male fertility

Taking a 3-month course of coenzyme Q10 supplements could improve semen quality among infertile men, show researchers.

16 Jan 2013

Acetaminophen may improve postoperative outcomes

Prophylactically administered intravenous acetaminophen could reduce postoperative nausea and vomiting, research suggests.

16 Jan 2013

Elan, Biogen Idec submit applications to FDA and EMA for updation of TYSABRI labels

Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.

16 Jan 2013

Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces completion of patient enrollment in the phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

16 Jan 2013

Pfizer’s Quillivant XR now available in the U.S. for treatment of ADHD

Pfizer Inc. today announced that Quillivant XR (methylphenidate hydrochloride) CII for extended-release oral suspension is now available in the U.S. for the treatment of attention deficit hyperactivity disorder (ADHD).

16 Jan 2013

New hope for people with sound-induced deafness

Preliminary results from a study in mice suggest it may be possible to regenerate cochlear hair cells that have been damaged due to excessive noise exposure.

15 Jan 2013

Vitamin D claims for knee osteoarthritis questioned

The benefit of taking vitamin D supplements for the treatment of knee osteoarthritis has been challenged in a study published in JAMA.

14 Jan 2013

Off-label drug ineffective in frontotemporal dementia

A randomized, controlled trial has dashed hopes that memantine therapy could benefit patients with frontotemporal dementia.

14 Jan 2013

Angiotensin II blockade does not seem to provide benefit to kidney transplant recipients

A drug that protects the kidneys of patients with chronic kidney disease does not seem to provide the same benefit to kidney transplant recipients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

11 Jan 2013

UCSF teams to study new ways to reduce childhood mortality and disease in developing nations

Two UCSF teams have received a total of $16 million from the Bill & Melinda Gates Foundation to study new ways to significantly reduce childhood mortality and disease in developing nations.

11 Jan 2013

Placing peanut protein under a patient's tongue helps dampen allergic reactions

Of all foods, peanuts are the most frequent cause of life-threatening and fatal allergic reactions. New research at National Jewish Health provides additional support for a strategy to reduce the severity of reactions to peanut- repeatedly consuming small amounts of the very food that causes those reactions in the first place, a practice called immunotherapy.

11 Jan 2013

Results from Morphotek’s farletuzumab Phase III combination study on ovarian cancer

Morphotek Inc., a wholly-owned subsidiary of Eisai Inc., announced today top-line results from a Phase III study of its investigational agent farletuzumab (MORAb-003) in combination with carboplatin and a taxane in patients with platinum-sensitive epithelial ovarian cancer in first relapse.

11 Jan 2013

LM11A-31 effective at improving limb movement after spinal cord injury in mice

An experimental oral drug given to mice after a spinal cord injury was effective at improving limb movement after the injury, a new study shows.

10 Jan 2013

Placebo News and Research

Allergan receives FDA approval for Botox to treat overactive bladder

Macular pigment screening: an interview with Jaquie Finn, Product Line Manager at Elektron Technology

Boehringer Ingelheim initiates enrollment in Phase III IFN-free HCV trial

Children's Oakland recruits patients for deferiprone clinical trial to treat PKAN

Underestimating cough duration may skew antibiotic perceptions

Top-line results from Amgen’s Aranesp Phase 3 trial on heart failure and anemia

Protein Sciences receives FDA approval for Flublok vaccine

Coenzyme Q10 supplement may boost male fertility

Acetaminophen may improve postoperative outcomes

Elan, Biogen Idec submit applications to FDA and EMA for updation of TYSABRI labels

Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

Pfizer’s Quillivant XR now available in the U.S. for treatment of ADHD

New hope for people with sound-induced deafness

Vitamin D claims for knee osteoarthritis questioned

Off-label drug ineffective in frontotemporal dementia

Angiotensin II blockade does not seem to provide benefit to kidney transplant recipients

UCSF teams to study new ways to reduce childhood mortality and disease in developing nations

Placing peanut protein under a patient's tongue helps dampen allergic reactions

Results from Morphotek’s farletuzumab Phase III combination study on ovarian cancer

LM11A-31 effective at improving limb movement after spinal cord injury in mice

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News